ClinicalTrials.gg
TerminatedNCT03292133Updated Jun 10, 2025Results posted

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

A Phase 2 interventional study of EGF816 and Gefitinib in Lung Cancer, sponsored by Massachusetts General Hospital. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-10.

Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Slow accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 49 studies in Lung Neoplasms by Massachusetts General Hospital — 17 open to participants now, 20 under way, none of them phase 3. Lung Neoplasms · Massachusetts General Hospital.

Enrollment
35th of 43
11 · median 46
Started
2017
with 6 others
Phase 2
10 of 49
2 open now
Registered
24th of 49
by date

Among the 49 studies in Lung Neoplasms by Massachusetts General Hospital, this one is the 35th largest by enrollment of the 43 interventional ones that give a count, is one of 7 that started in 2017, is one of 10 in phase 2, and was the 24th registered.

Lung Neoplasms

5,434 studies on the registry are indexed under Lung Neoplasms; 1,348 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

17 of the 49 studies in Lung Neoplasms by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 996 Lung Neoplasms studies recruiting now, 685 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Lung Neoplasms by Massachusetts General Hospital, or all of them as a file.
02

Study summary

This research study is studying a combination of drugs as a possible treatment for EGFR mutation-positive lung cancer.

The drugs involved in this study are:

  • EGF816
  • Gefitinib
Read the detailed description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease or patient population. "Investigational" means that the drug or drugs are being studied and have not been approved together for patients.

The FDA (the U.S. Food and Drug Administration) has approved gefitinib as a treatment option for EGFR mutation-positive lung cancer.

The FDA has not approved EGF816 as a treatment for any disease at this time.

In this research study, the investigators are studying the safety and efficacy of the combination of the study drugs EGF816 and gefitinib.

Both EGF816 and gefitinib are inhibitors which target a specific mutation in cancer and may stop tumors growing and multiplying.

03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a -confirmed diagnosis of non-small cell lung cancer (NSCLC).
  • Participants must have advanced disease - either stage IV disease, stage IIIB disease not amenable to definitive multi-modality therapy, or recurrent disease after a prior diagnosis of stage I-III disease. All staging is via the American Joint Committee on Cancer (AJCC)/IASLC 7th edition proposed staging criteria
  • An EGFR sensitizing mutation must be detected in tumor tissue. Specifically, patients harboring the most common mutations, deletions in exon 19 or the L858R mutation in exon 21 are eligible. Other EGFR sensitizing mutations may be eligible after discussion with the principal investigator. Patients may be enrolled in the study based on an activating EGFR mutation detected by a CLIA-certified tissue or plasma-based assay, but will be required to undergo a mandatory tumor during study screening.
  • Participants must have , per 1.1. See Section 11 for the evaluation of measurable disease.
  • Patients in the six patient safety run-in cohort may have had a prior EGFR TKI in the setting (to allow for patients who started initial therapy at an outside hospital), but treatment duration must have been less than three months. After the initial six-patient safety run-in, no prior EGFR TKI therapy in the metastatic setting is allowed. An EGFR TKI given in the setting (i.e. with no measurable disease at the time of administration) is allowable provided the subject has been off of EGFR TKI therapy for at least six months at the time of enrollment.
  • Patients may have had no more than one or immunotherapy in the metastatic setting. At least 14 days must have elapsed from the last chemo/immunotherapy administration until the start of protocol treatment, and patients must have recovered from the side effects of any of these agents.
  • Patients must be screened for . Patients who are either HBsAg positive or HBV-DNA positive must be willing and able to take antiviral therapy 1-2 weeks prior to 1st dose of study treatment and continue on antiviral therapy for at least 4 weeks after the last dose of EGF816. Additional management of the patients would be provided by a physician with expertise in management of HBV, if needed. Patients must have negative antibody (HCV-Ab) or positive HCV-Ab but undetectable level of HCV-RNA. Note: patients with detectable HCV-RNA are not eligible for the study.
  • Patients must receive insurance approval for or be willing to pay for commercial gefitinib.
  • Age >/= 18 years.
  • performance status ≤2 ( ≥60%, see Appendix A)
  • of greater than 12 weeks.
  • Participants must have normal organ and marrow function as defined below:

    • Leukocytes ≥3,000/mcL
    • ≥1,500/mcL
    • ≥100,000/mcL
    • Total >1.5 x (ULN)

      *For patients with Gilbert's syndrome total bilirubin >3.0 x ULN

    • (SGOT)/ALT(SGPT) ≤3 × institutional upper limit of normal; for patients with known hepatic metastases AST and/or ALT > 5x ULN
    • Creatinine ≤1.5 × institutional upper limit of normal
  • The effects of EGF816 and gefitinib on the developing human fetus are unknown. For this reason, women of and men must agree to use highly effective during the study and for 3 months after stopping the study treatment. Highly effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptom thermal, postovulation methods) and withdrawal are not acceptable methods of contraception
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
    • Male Partner: male sterilization (at least 6 months prior to screening). For female subjects on the study the vasectomized male partner should be the sole partner for that subject.
    • Combination of any two of the following (a+b or a+c, or b+c):
    • A. Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception.
    • B. Placement of an intrauterine device (IUD) or intrauterine system (IUS)
    • C. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.
    • D. In case of use of oral contraception women should have been stable on the same pill for a minimum of 30 days before taking study treatment.
    • Women are considered and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential.
    • Sexually active males must agree to use a condom during intercourse while taking drug and for 3 months after stopping treatment; men should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.
  • Ability to understand and the willingness to sign a written document. Written informed consent must be obtained prior to any screening procedures.

Exclusion criteria

Exclusion Criteria:

  • Participants with clinically active or symptomatic interstitial lung disease or interstitial pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention) and patients with history of interstitial lung disease or radiation pneumonitis.
  • Patients with clinically symptomatic or . Patients may be on a stable dose of to control brain metastases if they have been on a stable dose for two weeks prior to study treatment and are clinically asymptomatic.
  • Patients who have had radiation to the lung fields within four weeks of starting treatment. For patients receiving palliative radiation to thoracic vertebrae, ribs or other sites where the radiation field includes the lungs, radiation must be completed at least two weeks before starting treatment. For all palliative radiation to all other sites, at least 7 days must have elapsed prior to starting to treatment. At least six months must have elapsed from radiation given with curative intent.
  • Patients who have had major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 2 weeks prior to starting study drug or who have not recovered from side effects of such procedure. Video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the study ≥1 week after the procedure.
  • Patients unable or unwilling to undergo a for research during the screening period, 2-3 weeks into the course of therapy and at the time of progression.
  • Patients with a second, clinically active, cancer. Patients with second cancers which have been treated with curative intent and/or are currently inactive are allowed.
  • Patients who have undergone a bone marrow or solid organ transplant.
  • Known history of (HIV) seropositivity (HIV testing is not mandatory).
  • Participants who are receiving any other agents. Patients previously treated with investigational agents must complete a of at least one week or five half-lives, whichever is longer, before starting treatment.
  • Patients receiving concomitant agents or chronic corticosteroid use, except those on steroid to control brain metastases, those on topical or inhaled steroids, or steroids given via local injection.
  • Patients with clinically significant, uncontrolled cardiovascular disease, such as:

    • Unstable angina within 6 months prior to screening
    • Myocardial infarction within 6 months prior to screening
    • Patients with a history of documented congestive heart failure ( functional classification III-IV)
    • Peripheral vascular disease
    • Patients with uncontrolled hypertension defined as a Systolic Blood Pressure (SBP) ≥ 160 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 100 mm Hg, with or without anti-hypertensive medication. Initiation or adjustment of antihypertensive medication(s) is allowed prior to screening
    • Ventricular arrhythmias
    • Supraventricular and nodal arrhythmias not controlled with medication
    • Other cardiac arrhythmia not controlled with medication
    • Patients with (QTc) ≥450 ms (male patients) or ≥460 ms (female patients) using Fridericia correction (QTcF) on the screening (using triplicate ECGs)
    • Patients with history of congenital long QT syndrome or history of torsade de pointes
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to EGF816 or gefitinib.
  • Participants receiving any medications or substances that are strong inhibitors or inducers of are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list such as http://medicine.iupui.edu/clinpharm/ddis/table.aspx; medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment/ procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product.
  • Unable or unwilling to swallow tablets or capsules.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study because the effects of EGF816 and gefitinib on a developing fetus are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with EGF816 or gefitinib, breastfeeding should be discontinued if the mother is treated with EGF816 and gefitinib
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    EGF816 + Gefitinib

    * All patients will receive gefitinib orally once daily * EGF816 will be administered orally once daily * Participant will be requested to maintain a medication diary of each dose of medication

    Drug: EGF816 · Drug: Gefitinib

Interventions

  • DrugNazartinibStudies of NazartinibNazartinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    EGF816 is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying

  • Gefitinib is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying

    Also known as: Iressa

06

What researchers measure

Primary outcomes

  1. 9 Months Progression Free Rate

    The percentage of participants that are free from objective disease progression or death at 9 months after the start treatment. Progression is evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).

    Time frame: 9 months

Secondary outcomes

  1. Overall Response Rate (ORR)

    The number of participants that achieve either a complete response (CR) or a partial response (PR). Response is evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. All CRs and PRs must be confirmed by a second assessment not earlier than 4 weeks after the criteria for response are first met.

    Time frame: 4 years and 4 months

  2. Median Overall Survival

    Overall survival is defined as time from the start of treatment until death or loss to follow up. Overall survival will be analyzed using the Kaplan-Meier method.

    Time frame: 6 years

  3. Median Progression Free Survival (PFS)

    PFS is defined as the time from start of treatment to the time of objective disease progression, death, or loss to follow up. Progression is evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).

    Time frame: 4.2 years

  4. Summary of Treatment-related Adverse Events

    Treatment-related adverse events, defined as those at least possibly related to study treatment, are summarized below as a measure of patient safety and treatment tolerability. Subjects were evaluated for adverse events by the Common Terminology Criteria for Adverse Events (CTCAE) v4. For each treatment-related event, subjects are counted below by the highest grade they experienced on study per CTCAE v 4.0 to demonstrate the range and severity of treatment-related toxicities documented on study. Grade refers to the severity of the toxicity, with Grade 1 corresponding to mild toxicity, Grade 2 to moderate toxicity, and Grade 3 to severe toxicity. Patients who did not experience a given event at any grade are counted in the final category for each row.

    Time frame: Start of treatment through 30 days after the end of treatment (max 4 years and 5 months)

07

Results

Posted Jun 10, 2025
Limitations and caveats
While the original sample size was planned to be 36 patients, only 11 patients were enrolled, as the study was terminated early due to slow accrual.

Participant flow

Participant flow — Overall Study
MilestoneEGF816 + Gefitinib
Started11
Completed11
Not completed0

Outcome measures

Primary9 Months Progression Free Rate

The percentage of participants that are free from objective disease progression or death at 9 months after the start treatment. Progression is evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).

Time frame:
9 months
Reported as:
Count of participants · Participants
9 Months Progression Free Rate
ParticipantsEGF816 + Gefitinib
9 Months Progression Free Rate7
SecondaryOverall Response Rate (ORR)

The number of participants that achieve either a complete response (CR) or a partial response (PR). Response is evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. All CRs and PRs must be confirmed by a second assessment not earlier than 4 weeks after the criteria for response are first met.

Time frame:
4 years and 4 months
Reported as:
Count of participants · Participants
Overall Response Rate (ORR)
ParticipantsEGF816 + Gefitinib
Overall Response Rate (ORR)8
SecondaryMedian Overall Survival

Overall survival is defined as time from the start of treatment until death or loss to follow up. Overall survival will be analyzed using the Kaplan-Meier method.

Time frame:
6 years
Reported as:
Median · months
Median Overall Survival
monthsEGF816 + Gefitinib
Median Overall Survival35.7 (6.18 to NA)
SecondaryMedian Progression Free Survival (PFS)

PFS is defined as the time from start of treatment to the time of objective disease progression, death, or loss to follow up. Progression is evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).

Time frame:
4.2 years
Reported as:
Median · months
Median Progression Free Survival (PFS)
monthsEGF816 + Gefitinib
Median Progression Free Survival (PFS)20.86 (5.42 to 39.57)
SecondarySummary of Treatment-related Adverse Events

Treatment-related adverse events, defined as those at least possibly related to study treatment, are summarized below as a measure of patient safety and treatment tolerability. Subjects were evaluated for adverse events by the Common Terminology Criteria for Adverse Events (CTCAE) v4. For each treatment-related event, subjects are counted below by the highest grade they experienced on study per CTCAE v 4.0 to demonstrate the range and severity of treatment-related toxicities documented on study. Grade refers to the severity of the toxicity, with Grade 1 corresponding to mild toxicity, Grade 2 to moderate toxicity, and Grade 3 to severe toxicity. Patients who did not experience a given event at any grade are counted in the final category for each row.

Time frame:
Start of treatment through 30 days after the end of treatment (max 4 years and 5 months)
Reported as:
Count of participants · Participants
Summary of Treatment-related Adverse Events
ParticipantsEGF816 + Gefitinib
Anemia — Grade 1 (CTCAE v4)1
Anemia — Grade 2 (CTCAE v4)0
Anemia — Grade 3 (CTCAE v4)0
Anemia — Subject did not experience this treatment-related toxicity10
Cardiac disorders - other, specify — Grade 1 (CTCAE v4)0
Cardiac disorders - other, specify — Grade 2 (CTCAE v4)1
Cardiac disorders - other, specify — Grade 3 (CTCAE v4)0
Cardiac disorders - other, specify — Subject did not experience this treatment-related toxicity10
Dry eye — Grade 1 (CTCAE v4)1
Dry eye — Grade 2 (CTCAE v4)0
Dry eye — Grade 3 (CTCAE v4)0
Dry eye — Subject did not experience this treatment-related toxicity10
Eye Pain — Grade 1 (CTCAE v4)1
Eye Pain — Grade 2 (CTCAE v4)0
Eye Pain — Grade 3 (CTCAE v4)0
Eye Pain — Subject did not experience this treatment-related toxicity10
Abdominal Pain — Grade 1 (CTCAE v4)1
Abdominal Pain — Grade 2 (CTCAE v4)0
Abdominal Pain — Grade 3 (CTCAE v4)0
Abdominal Pain — Subject did not experience this treatment-related toxicity10
Bloating — Grade 1 (CTCAE v4)1
Bloating — Grade 2 (CTCAE v4)0
Bloating — Grade 3 (CTCAE v4)0
Bloating — Subject did not experience this treatment-related toxicity10
Diarrhea — Grade 1 (CTCAE v4)6
Diarrhea — Grade 2 (CTCAE v4)3
Diarrhea — Grade 3 (CTCAE v4)2
Diarrhea — Subject did not experience this treatment-related toxicity0
Dry mouth — Grade 1 (CTCAE v4)3
Dry mouth — Grade 2 (CTCAE v4)0
Dry mouth — Grade 3 (CTCAE v4)0
Dry mouth — Subject did not experience this treatment-related toxicity8
Dyspepsia — Grade 1 (CTCAE v4)1
Dyspepsia — Grade 2 (CTCAE v4)0
Dyspepsia — Grade 3 (CTCAE v4)0
Dyspepsia — Subject did not experience this treatment-related toxicity10
Gastroesophageal Reflux disease — Grade 1 (CTCAE v4)1
Gastroesophageal Reflux disease — Grade 2 (CTCAE v4)0
Gastroesophageal Reflux disease — Grade 3 (CTCAE v4)0
Gastroesophageal Reflux disease — Subject did not experience this treatment-related toxicity10
Gastrointestinal disorders - other, specify — Grade 1 (CTCAE v4)1
Gastrointestinal disorders - other, specify — Grade 2 (CTCAE v4)1
Gastrointestinal disorders - other, specify — Grade 3 (CTCAE v4)0
Gastrointestinal disorders - other, specify — Subject did not experience this treatment-related toxicity9
Mucositis oral — Grade 1 (CTCAE v4)1
Mucositis oral — Grade 2 (CTCAE v4)2
Mucositis oral — Grade 3 (CTCAE v4)0
Mucositis oral — Subject did not experience this treatment-related toxicity8
Nausea — Grade 1 (CTCAE v4)2
Nausea — Grade 2 (CTCAE v4)0
Nausea — Grade 3 (CTCAE v4)0
Nausea — Subject did not experience this treatment-related toxicity9
Oral pain — Grade 1 (CTCAE v4)0
Oral pain — Grade 2 (CTCAE v4)1
Oral pain — Grade 3 (CTCAE v4)0
Oral pain — Subject did not experience this treatment-related toxicity10
Fatigue — Grade 1 (CTCAE v4)3
Fatigue — Grade 2 (CTCAE v4)0
Fatigue — Grade 3 (CTCAE v4)0
Fatigue — Subject did not experience this treatment-related toxicity8
Fever — Grade 1 (CTCAE v4)0
Fever — Grade 2 (CTCAE v4)0
Fever — Grade 3 (CTCAE v4)1
Fever — Subject did not experience this treatment-related toxicity10
Paronychia — Grade 1 (CTCAE v4)2
Paronychia — Grade 2 (CTCAE v4)2
Paronychia — Grade 3 (CTCAE v4)0
Paronychia — Subject did not experience this treatment-related toxicity7
Alanine aminotransferase increased — Grade 1 (CTCAE v4)3
Alanine aminotransferase increased — Grade 2 (CTCAE v4)2
Alanine aminotransferase increased — Grade 3 (CTCAE v4)0
Alanine aminotransferase increased — Subject did not experience this treatment-related toxicity6
Aspartate aminotransferase increased — Grade 1 (CTCAE v4)4
Aspartate aminotransferase increased — Grade 2 (CTCAE v4)0
Aspartate aminotransferase increased — Grade 3 (CTCAE v4)0
Aspartate aminotransferase increased — Subject did not experience this treatment-related toxicity7
Electrocardiogram QT corrected interval prolonged — Grade 1 (CTCAE v4)1
Electrocardiogram QT corrected interval prolonged — Grade 2 (CTCAE v4)0
Electrocardiogram QT corrected interval prolonged — Grade 3 (CTCAE v4)0
Electrocardiogram QT corrected interval prolonged — Subject did not experience this treatment-related toxicity10
Neutrophil count decreased — Grade 1 (CTCAE v4)2
Neutrophil count decreased — Grade 2 (CTCAE v4)0
Neutrophil count decreased — Grade 3 (CTCAE v4)0
Neutrophil count decreased — Subject did not experience this treatment-related toxicity9
Weight gain — Grade 1 (CTCAE v4)1
Weight gain — Grade 2 (CTCAE v4)0
Weight gain — Grade 3 (CTCAE v4)0
Weight gain — Subject did not experience this treatment-related toxicity10
Anorexia — Grade 1 (CTCAE v4)1
Anorexia — Grade 2 (CTCAE v4)0
Anorexia — Grade 3 (CTCAE v4)0
Anorexia — Subject did not experience this treatment-related toxicity10
Hypomagnesemia — Grade 1 (CTCAE v4)1
Hypomagnesemia — Grade 2 (CTCAE v4)0
Hypomagnesemia — Grade 3 (CTCAE v4)0
Hypomagnesemia — Subject did not experience this treatment-related toxicity10
Hyponatremia — Grade 1 (CTCAE v4)1
Hyponatremia — Grade 2 (CTCAE v4)0
Hyponatremia — Grade 3 (CTCAE v4)0
Hyponatremia — Subject did not experience this treatment-related toxicity10
Metabolism and nutrition disorders - other, specify — Grade 1 (CTCAE v4)1
Metabolism and nutrition disorders - other, specify — Grade 2 (CTCAE v4)0
Metabolism and nutrition disorders - other, specify — Grade 3 (CTCAE v4)0
Metabolism and nutrition disorders - other, specify — Subject did not experience this treatment-related toxicity10
Arthralgia — Grade 1 (CTCAE v4)1
Arthralgia — Grade 2 (CTCAE v4)0
Arthralgia — Grade 3 (CTCAE v4)0
Arthralgia — Subject did not experience this treatment-related toxicity10
Myalgia — Grade 1 (CTCAE v4)3
Myalgia — Grade 2 (CTCAE v4)0
Myalgia — Grade 3 (CTCAE v4)0
Myalgia — Subject did not experience this treatment-related toxicity8
Renal and urinary disorders - other, specify — Grade 1 (CTCAE v4)1
Renal and urinary disorders - other, specify — Grade 2 (CTCAE v4)0
Renal and urinary disorders - other, specify — Grade 3 (CTCAE v4)0
Renal and urinary disorders - other, specify — Subject did not experience this treatment-related toxicity10
Erectile dysfunction — Grade 1 (CTCAE v4)1
Erectile dysfunction — Grade 2 (CTCAE v4)0
Erectile dysfunction — Grade 3 (CTCAE v4)0
Erectile dysfunction — Subject did not experience this treatment-related toxicity10
Vaginal pain — Grade 1 (CTCAE v4)1
Vaginal pain — Grade 2 (CTCAE v4)0
Vaginal pain — Grade 3 (CTCAE v4)0
Vaginal pain — Subject did not experience this treatment-related toxicity10
Cough — Grade 1 (CTCAE v4)0
Cough — Grade 2 (CTCAE v4)1
Cough — Grade 3 (CTCAE v4)0
Cough — Subject did not experience this treatment-related toxicity10
Dyspnea — Grade 1 (CTCAE v4)0
Dyspnea — Grade 2 (CTCAE v4)1
Dyspnea — Grade 3 (CTCAE v4)0
Dyspnea — Subject did not experience this treatment-related toxicity10
Epistaxis — Grade 1 (CTCAE v4)1
Epistaxis — Grade 2 (CTCAE v4)0
Epistaxis — Grade 3 (CTCAE v4)0
Epistaxis — Subject did not experience this treatment-related toxicity10
Pneumonitis — Grade 1 (CTCAE v4)0
Pneumonitis — Grade 2 (CTCAE v4)1
Pneumonitis — Grade 3 (CTCAE v4)0
Pneumonitis — Subject did not experience this treatment-related toxicity10
Sore throat — Grade 1 (CTCAE v4)0
Sore throat — Grade 2 (CTCAE v4)1
Sore throat — Grade 3 (CTCAE v4)0
Sore throat — Subject did not experience this treatment-related toxicity10
Alopecia — Grade 1 (CTCAE v4)1
Alopecia — Grade 2 (CTCAE v4)1
Alopecia — Grade 3 (CTCAE v4)0
Alopecia — Subject did not experience this treatment-related toxicity9
Bullous dermatitis — Grade 1 (CTCAE v4)0
Bullous dermatitis — Grade 2 (CTCAE v4)1
Bullous dermatitis — Grade 3 (CTCAE v4)0
Bullous dermatitis — Subject did not experience this treatment-related toxicity10
Dry skin — Grade 1 (CTCAE v4)4
Dry skin — Grade 2 (CTCAE v4)1
Dry skin — Grade 3 (CTCAE v4)0
Dry skin — Subject did not experience this treatment-related toxicity6
Erythema multiforme — Grade 1 (CTCAE v4)2
Erythema multiforme — Grade 2 (CTCAE v4)0
Erythema multiforme — Grade 3 (CTCAE v4)0
Erythema multiforme — Subject did not experience this treatment-related toxicity9
Pain of skin — Grade 1 (CTCAE v4)1
Pain of skin — Grade 2 (CTCAE v4)1
Pain of skin — Grade 3 (CTCAE v4)0
Pain of skin — Subject did not experience this treatment-related toxicity9
Pruritis — Grade 1 (CTCAE v4)4
Pruritis — Grade 2 (CTCAE v4)1
Pruritis — Grade 3 (CTCAE v4)0
Pruritis — Subject did not experience this treatment-related toxicity6
Rash acneiform — Grade 1 (CTCAE v4)5
Rash acneiform — Grade 2 (CTCAE v4)2
Rash acneiform — Grade 3 (CTCAE v4)0
Rash acneiform — Subject did not experience this treatment-related toxicity4
Rash maculo-papular — Grade 1 (CTCAE v4)3
Rash maculo-papular — Grade 2 (CTCAE v4)2
Rash maculo-papular — Grade 3 (CTCAE v4)3
Rash maculo-papular — Subject did not experience this treatment-related toxicity3
Scalp pain — Grade 1 (CTCAE v4)1
Scalp pain — Grade 2 (CTCAE v4)0
Scalp pain — Grade 3 (CTCAE v4)0
Scalp pain — Subject did not experience this treatment-related toxicity10
Skin/subcutaneous tissue disorders - other, specify — Grade 1 (CTCAE v4)3
Skin/subcutaneous tissue disorders - other, specify — Grade 2 (CTCAE v4)1
Skin/subcutaneous tissue disorders - other, specify — Grade 3 (CTCAE v4)0
Skin/subcutaneous tissue disorders - other, specify — Subject did not experience this treatment-related toxicity7

Adverse events

Collected over Adverse events are collected from informed consent until 30 days after the end of treatment (maximum 4 years and 5 months). Patients were monitored for survival up to 6 years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EGF816 + Gefitinib4/11 (36.4%)2/11 (18.2%)11/11 (100%)
Most frequent serious events
Most frequent serious events
EventEGF816 + Gefitinib
FeverGeneral disorders1/11
Pericardial effusionCardiac disorders1/11
Most frequent other events
Showing 10 of 104
Most frequent other events
EventEGF816 + Gefitinib
DiarrheaGastrointestinal disorders11/11
Rash maculo-papularSkin and subcutaneous tissue disorders8/11
DyspneaRespiratory, thoracic and mediastinal disorders7/11
Rash acneiformSkin and subcutaneous tissue disorders7/11
CoughRespiratory, thoracic and mediastinal disorders6/11
FatigueGeneral disorders6/11
Alanine aminotransferase increasedInvestigations5/11
Dry skinSkin and subcutaneous tissue disorders5/11
FeverGeneral disorders5/11
HypertensionVascular disorders5/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)EGF816 + Gefitinib
Median58 (47 to 72)
Sex: Female, Male
Sex: Female, Male(Participants)EGF816 + Gefitinib
Female5
Male6
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EGF816 + Gefitinib
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American1
White7
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02214, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Dec 2021, 50 months.

Results were first posted in Jun 2025, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2017
First posted
Sep 25, 2017
StartActual
Oct 31, 2017
Primary completionActual
Dec 31, 2021
CompletionActual
Mar 4, 2025
Results first posted
Jun 10, 2025
Last update
Jun 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03292133
Collaborators
Novartis
Responsible party
Zofia Piotrowska (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Sep 25, 2017
Start date
Oct 31, 2017
Primary completion
Dec 31, 2021
Completion
Mar 4, 2025
Results posted
Jun 10, 2025
Last update
Jun 10, 2025

Study contacts

Zofia Piotrowska, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nazartinib

Start the discussion